New drug combo aims to boost breast cancer remission before surgery
NCT ID NCT07178171
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new immunotherapy drug (QL1706) combined with short cycles of chemotherapy in 30 people with early-stage triple-negative breast cancer. The goal is to see if this approach can eliminate all signs of cancer before surgery. Participants receive either a taxane or an anthracycline chemo alongside the immunotherapy, and those who still have cancer after initial treatment get additional cycles.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xijing hospital
RECRUITINGXi'an, Shaanxi, 710032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••